Clinical Policy: Pediatric Heart Transplant
Customize your policy alerts
Sign up for Arizona Complete Health Policy CP.MP.138 alerts
Get alerted when Policy CP.MP.138 changes without checking for updates manually.
Monitor payer policy activity
Medical necessity criteria and coverage guidance for heart transplantation and re-transplantation in pediatric members/enrollees (age < 18) including candidate indications, contraindications, and required evaluations.
Added additional criterion addressing pulmonary hypertension with potential risk of developing fixed, irreversible elevation of pulmonary vascular resistance that could preclude orthotopic heart transplantation.
Updated contraindication glomerular filtration rate threshold from < 40 mL/min/1.73m2 to < 30 mL/min/1.73m2.
Expanded qualifying criteria for HIV-positive members to allow consideration when CD4, viral load control, absence of active opportunistic infections, and effective ART are documented.
Removed BMI appendix and related tables; edited BMI-related contraindication language.
Coverage Criteria for Pediatric Heart Transplantation
inv-01: Initial pediatric heart transplant — covered when ALL of the following are met
Covered when ALL of the following are met:
Supports primary pediatric heart transplant candidacy.
inv-02: Re-transplantation — covered when ALL of the following are met
Covered when ALL of the following are met:
Re-transplantation is not appropriate during an episode of ongoing acute allograft rejection or within the first six months after primary transplantation (see exclusions).
inv-03: General candidate requirements
Covered when ALL of the following are met:
The policy lists explicit contraindications to pediatric heart transplantation. Important absolute or near-absolute exclusions include a glomerular filtration rate (GFR) < 30 mL/min/1.73m2 unless the member is being considered for a multiorgan transplant, and severe, irreversible, fixed pulmonary vascular resistance that precludes orthotopic transplant. Other contraindications include severe hypoplasia of central branch pulmonary arteries or pulmonary veins; certain congenital heart lesions except where specifically allowed; and amyloid light-chain (AL) amyloidosis unless curative therapy has been performed or is planned (examples provided include stem cell transplant or liver transplant in familial forms).
The policy also identifies situational and social contraindications such as active, poorly controlled infections (including active tuberculosis and chronic infection with highly virulent or resistant organisms), malignancy with high risk of recurrence or death, advanced liver disease or cirrhosis (unless multiorgan transplant is planned), acute renal failure with low likelihood of recovery, progressive cognitive impairment, significant chest wall or spinal deformity expected to cause severe restriction, inability to adhere to required post‑transplant regimens despite caregiver support, absence of adequate social support, and active substance use or dependence (including current tobacco/vaping/marijuana or IV drug use) unless convincing evidence of risk-reduction or urgent timelines with commitment to behavior change are documented.
Re-transplantation is allowed for specified indications (for example, moderate to severe cardiac graft vasculopathy) but the policy explicitly excludes re-transplantation performed during an episode of ongoing acute allograft rejection and within the first six months after primary transplantation. Such timing-related exclusions are considered contraindications and will render a re-transplant request inappropriate until the episode of rejection is resolved or until the six-month post-transplant interval has passed.
Candidate Eligibility Requirements
inv-14: Candidate eligibility — Candidate must meet indication and general requirements
Candidate must meet indication and general requirements:
Contraindications to Transplant
Key contraindications and required thresholds include a GFR < 30 mL/min/1.73m2 (unless the candidate is being evaluated for multiorgan transplant). For candidates with HIV, transplantation may be considered only when the record documents CD4 > 200 cells/mm3, absence of active AIDS-defining opportunistic infection (unless treated/prevented), and that the member is on effective antiretroviral therapy (ART).
Additional contraindications affecting candidacy include severe, irreversible fixed elevation of pulmonary vascular resistance; severe hypoplasia of central pulmonary arteries/veins; AL amyloidosis without planned curative therapy; active tuberculosis; malignancy with high recurrence risk; advanced liver disease or cirrhosis absent multiorgan plan; acute renal failure with rising creatinine or dialysis and low recovery likelihood; inability to adhere to required regimens even with caregiver support; absence of adequate social support; progressive cognitive impairment; and active substance use or dependence without convincing risk-reduction evidence. These conditions should be documented and considered when determining eligibility.
Pre-Transplant Evaluation Requirements
Rule out reversible causes of heart failure
All reversible causes of heart failure must be evaluated and documented as ruled out prior to consideration for transplant. Examples listed in the policy include anemia, hypertension, renal failure, acidosis, obesity, malnutrition, respiratory disorders, and thyroid disorders.
- Document evaluation and exclusion of reversible medical contributors (e.g., anemia, hypertension, renal failure, acidosis).
- Document assessment and management of metabolic/nutritional and endocrine contributors (e.g., obesity, malnutrition, thyroid disorders).
- Document evaluation and treatment of respiratory contributors prior to listing.
Provider Actions and Documentation
Step therapy not applicable
Step therapy does not apply to transplant candidacy; the policy specifies transplant medical necessity criteria rather than staged pharmacologic therapy requirements.
Provide required supporting documentation
Documentation must demonstrate the indication for transplant and that general candidate requirements are met, including life expectancy ≥ 2 years absent cardiopulmonary disease, ruling out all reversible causes of heart failure, and absence of listed contraindications; for HIV-positive candidates, document CD4 >200 cells/mm3, absence of active AIDS-defining opportunistic infection (unless treated/prevented), and that the member is on effective antiretroviral therapy.
- Evidence of stage D heart failure or specified stage C criteria (e.g., peak VO2 < 50% predicted, growth failure, refractory arrhythmia, reactive pulmonary hypertension).
- Life expectancy estimate ≥ 2 years without cardiopulmonary disease.
- Specific HIV documentation: CD4 >200 cells/mm3, absence of active AIDS-defining infection, and current effective ART.
Common triggers for denial
Requests may be denied if the member does not meet the medical necessity criteria, has any listed contraindications (for example, GFR < 30 mL/min/1.73m2, active tuberculosis, uncontrolled or highly virulent/resistant infections, malignancy with high recurrence risk, active substance use), or if reversible causes of heart failure have not been ruled out.
- Insufficient documentation of meeting indication or life expectancy criteria.
- Presence of any exclusion such as GFR < 30 mL/min/1.73m2 (unless multiorgan transplant consideration), active tuberculosis, or uncontrolled infection.
- Retransplant requests during ongoing acute allograft rejection or within six months of primary transplant.
Coding and Key Clinical Thresholds
| 33944 | Backbench standard preparation of cadaver donor heart allograft prior to transplantation, including dissection of allograft from surrounding soft tissues to prepare aorta, superior vena cava, inferior vena cava, pulmonary artery, and left atrium for implantation. |
| 33945 | Heart transplant, with or without recipient cardiectomy |
Post-Transplant Outcomes and Coverage Notes
Definitions and Clinical Staging
Center and Program Requirements
Center evaluation and standards
The policy references general standards and expectations for candidate evaluation but does not enumerate specific center accreditation, volume, or certification requirements in the extracted text; providers should follow standard transplant center practice and include center evaluation documentation with authorization requests.
- Include documentation of transplant center evaluation and multidisciplinary assessment when submitting prior authorization.
- If applicable, document any center-specific assessments that demonstrate candidate suitability per policy criteria.
Background and Clinical Context
Pediatric cardiomyopathies and congenital heart disease encompass a broad spectrum of disorders that can progress to end-stage heart failure requiring transplantation. Dilated cardiomyopathy is among the most common indications in children, but anatomic indications—such as certain severe lesions or complications after palliative surgery in single-ventricle infants—also justify listing for transplant when they predict poor natural history.
Survival after pediatric heart transplantation is generally favorable in the early post‑transplant period but varies by age and other factors. The policy frames transplant candidacy within clinical stages of heart failure and specifies that candidates should have a projected life expectancy of at least 2 years in the absence of cardiopulmonary disease and that all reversible causes of heart failure be evaluated and ruled out prior to listing.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.